Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBT-102
- Development stage
- Preclinical
- Lead developer
- Singh Biotechnology
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
SBT-102 is a cell-penetrating single domain antibody (sdAb) developed by Singh Biotechnology that targets the KRAS protein. It is designed to penetrate the cell membrane and bind to intracellular KRAS, inhibiting its GTPase activity. This inhibition disrupts downstream signaling through the MAPK pathway, specifically reducing levels of phosphorylated ERK (P-ERK), which is a key driver of cell proliferation in cancers harboring KRAS mutations, such as pancreatic, colorectal, and lung cancers. While closely related to SBT-100, SBT-102 has demonstrated significant in vitro inhibition of KRAS GTPase activity comparable to polyclonal antibodies.
02
Targets
Beyond the preview
Go deeper on SBT-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBT-102.